These findings are promising because an anti-IL-6 agent (siltuximab) has already been approved by the United States Food and Drug Administration (FDA) to treat patients with Castleman’s disease (http://www.cancer.org//cancer/new/fda-approves-sylvant-siltuximab-for-castleman-disease). This evidence concerns the gene IL6 and Castleman disease.